Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients

Hospital Authority, Hong Kong

Status

Completed

Conditions

Laryngitis

Gastroesophageal Reflux

Treatments

Drug: Rabeprazole 20mg twice daily

Study type

Interventional

Funder types

Other

Identifiers

NCT00517114

HARECCTR0500033

UW04-204 T/526

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy of rabeprazole (pariet) versus placebo in treating reflux laryngitis in Chinese patients. Patients who attend the voice clinic of Department of ENT, Queen Mary hospital with suspected reflux laryngitis will be recruited. A questionnaire will be administered by the research assistant of the Department of Medicine and ENT, Queen Mary hospital. A 12-week course of PPI versus placebo trial will be commenced and patients' symptoms and signs will be documented at 6-week and 12-week time. The study will finish after a 12-week course of rabeprazole.

Enrollment

200 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ambulatory patients with age between 18-80 years old
Patients with newly presented laryngitis.

Exclusion criteria

They were under 18 or over 80 years of age
Has significant concomitant medical disease
Pregnancy or lactating women
Chronic cough attributable to known chronic pulmonary or tracheobronchial disease
Previous glottal surgery, radiotherapy or malignancy
Acid suppressive therapy within 4 wk prior to recruitment
Pharyngo-laryngeal infection in the previous 3 months
Tracheal intubation in previous 12 months
Immunosuppression and use of inhaled corticosteroid